New Unexpected Data on Non-Culprit Vessels in MI

Patients with acute myocardial infarction presenting lesions in multiple vessels is not associated with reduced infarct size in non-culprit lesions, even when functionally significant. 

Nueva y discrepante información sobre los vasos no culpables en el infarto

Animal models suggest brief periods of ischemia in non-infarct territories (non-culprit) might protect culprit territory thanks to remote ischemic preconditioning.  This pre-conditioning, according to this perspective, would reduce reperfusion injury and translate into reduced infarct size. 

Ischemic preconditioning model may be used in patients with functionally significant lesions in other vessels presenting MI. 

The aim of this stud was to look into the link between functional multivessel disease and reduced infarct size in a large contemporary cohort of patients

A cardiac MR was done in 610 patients undergoing primary PCI on day 1 and after 3 months

Patients were stratified in 3 groups according to FFR measurements in non-culprit lesions: angiographic single vessel disease, FFR nonsignificant single vessel disease, or FFR-significant functional multivessel disease. 


Read also: The Key to Treating Stroke: Knowing When to Stop.


431 patients presented angiographic single vessel disease (71%), 35 had functional single vessel disease (6%) and 144 had functional multivessel disease (23%).

There were no significant differences in infarct size or myocardial salvage index between groups. Functional multivessel disease was not associated with larger myocardial salvage (p=0.56) or smaller infarct size (p=0.55).

These outcomes raise questions about remote ischemic pre-conditioning. 

Conclusion

Functional multivessel disease in patients undergoing primary PCI is not associated to reduced infarct size or improve myocardial salvage index.  This is important information for future cardioprotective treatment of MI patients. 

Título original: Ischemia From Nonculprit Stenosis Is Not Associated With Reduced Culprit Infarct Size in Patients with ST-Segment–Elevation Myocardial Infarction.

Referencia: Kathrine Ekström et al. Circ Cardiovasc Imaging. 2021 May 5. Online ahead of print. doi: 10.1161/CIRCIMAGING.120.012290. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....